Université Clermont Auvergne, INRAE, UNH, UMR1019, Clermont-Ferrand, France.
Medical Oncology Department, CHU Gabriel Montpied, Clermont-Ferrand, France.
HLA. 2024 Jan;103(1):e15252. doi: 10.1111/tan.15252. Epub 2023 Oct 17.
T cell therapy strategies, from allogeneic stem cell transplantation toward genetically-modified T cells infusion, develop powerful anti-tumor effects but are often accompanied by side effects and their efficacy remains sometimes to be improved. It therefore appears important to provide a flexible and easily reversible gene expression regulation system to control T cells activity. We developed a gene expression regulation technology that exploits the physiological GCN2-ATF4 pathway's ability to induce gene expression in T cells in response to one essential amino acid deficiency. We first demonstrated the functionality of NUTRIREG in human T cells by transient expression of reporter genes. We then validated that NUTRIREG can be used in human T cells to transiently express a therapeutic gene such as IL-10. Overall, our results represent a solid basis for the promising use of NUTRIREG to regulate transgene expression in human T cells in a reversible way, and more generally for numerous preventive or curative therapeutic possibilities in cellular immunotherapy strategies.
T 细胞治疗策略,从异体干细胞移植到基因修饰 T 细胞输注,都具有强大的抗肿瘤作用,但常伴有副作用,其疗效有时仍有待提高。因此,提供一种灵活且易于逆转的基因表达调控系统来控制 T 细胞的活性非常重要。我们开发了一种基因表达调控技术,利用生理 GCN2-ATF4 途径在 T 细胞中诱导基因表达的能力,以响应一种必需氨基酸的缺乏。我们首先通过瞬时表达报告基因证明了 NUTRIREG 在人 T 细胞中的功能。然后,我们验证了 NUTRIREG 可用于人 T 细胞中瞬时表达治疗基因,如 IL-10。总的来说,我们的结果为 NUTRIREG 以可逆的方式在人 T 细胞中调控转基因表达提供了坚实的基础,更广泛地为细胞免疫治疗策略中的许多预防性或治疗性治疗可能性提供了基础。